Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Not yet recruitingPhase 4NCT07664956
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.
Study details
- Official title
- Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial
- Conditions
- Minimally Invasive Surgical Procedures
- Abnormal Uterine Bleeding, Unspecified
- Adenomyosis of Uterus
- Fibroid Uterus
- Chronic Pelvic Pain
- Endometriosis
- Menorrhagia
- Endometritis
- Adnexal Diseases
- Interventions
- Drug: Cyclobenzaprine
- Sponsor
- Christiana Care Health Services
- Start date
- 2026-07-01
- Primary completion
- 2026-09-01
- Sex
- Female
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age \>18yo * Female * English speaking * Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy * If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included * Surgery took place at ChristianaCare Hospitals * No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine Exclusion Criteria: * Age \<18yo * Male * Pregnant, breastfeeding * Non-English speaking * Primary procedures other than laparoscopic hysterectomy * Laparoscopic myomectomy * Laparoscopic resection of endometriosis * Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy * Hysteroscopic procedures * Bartholin gland marsupialization * Operations that are scheduled as or converted to the open approach * Procedures with planned or unplanned bladder or bowel surgery * Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc. * Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management * Currently undergoing medication assisted treatment for opioid use disorder * Currently using opioids consistently * Allergies or contraindications to cyclobenzaprine: * Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome * Allergies or contraindications to inactive ingredients in Flexeril, such as lactose * Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07664956